May 12th 2017
PARIS, France and CAMBRIDGE, MA, US – May 12th 2017 – Lysogene (FR0013233475 – LYS), a leading clinical-stage biopharmaceutical company specializing in gene therapy technology applied to central nervous system diseases, announced today that Karen Aiach, CEO and Founder of Lysogene, won the Women’s Entrepreneurship’s Innovation & New Technologies Trophy – co-organized by the Women’s Entrepreneurship Association and the CPME – rewarding her “spectacular breakthrough in the exclusive arena of rare diseases.”
On Thursday 11th, during the prestigious ceremony held at the Economic, Social and Environmental Counsel in Paris, and hosted by François Asselin, Chairman of CPME, the jury rewarded an « entrepreneurial mother’s tenacity » and applauded that a “family issue turned into a medical research and entrepreneurial goal”.
According to François Asselin, « these trophies highlight talented, resourceful, bold and tough female directors who launch and establish their companies abroad in order to promote the entrepreneurship “à la française”.”
“I am greatly touched by this reward. I dedicate it to children suffering from rare diseases and their families, as well as to my own team and shareholders who believe in Lysogene” said Karen Aiach. “I am proud to run a company where diversity goes without saying. I will always fight so that women occupy the place they deserve in the business world.”
About the Women’s Entrepreneurship Association
The association aims to help and promote female entrepreneurship in France and abroad, including the promotion of female business directors’ role in economic life, or the defense of
1 French Small and Mid-Caps Confederation
female business directors’ rights and interests. For more information: https://www.eaf- club.com/
The CPME – French Small and Mid-Caps Confederation – is a private, independent, inter-branch employer organization, whose representativeness is officially accepted. It ensures all sectored – industry, trades, services, craftsmanship – small and mid-caps’ representation and defense, both at national level – alongside public authorities and social partners – and international level. It simultaneously gathers professional federations, trade unions and territorial structures. For more information: http://www.cpme.fr/
Lysogene is a leading, clinical stage biotechnology company, specializing in the basic research and clinical development of AAV gene therapy for CNS disorders with a high unmet medical need. Since 2009, Lysogene has established a solid platform and network, with lead products in Mucopolysaccharidosis Type IIIA and GM1 Gangliosidosis, to become a global leader in orphan CNS diseases. Lysogene has also obtained ODD by the EMA and FDA and rare pediatric designation by the FDA for both its MPS IIIA and GM1 programs.
Lysogene is listed on the Euronext regulated market in Paris (ISIN code: FR0013233475) For more information, please visit www.lysogene.com.
|Annie-Florence Loyer||Chris Maggos|
|+ 33 6 88 20 35 59||+41 79 367 6254|
|+ 33 1 44 71 00 12|
|+ 1 (212) 223-4017|